There have been considerable advances in our understanding of renal cell carcinoma, which have been translated into the development of several drugs with proven efficacy, with kinase inhibitors demonstrating significant activity. The authors of this review discuss the targeted agents that have proved efficacious in the difficult-to-treat metastatic setting, and highlight the issues of patient selection, scheduling, dose, duration of treatment, potential combinations and toxicity.
- James MG Larkin
- Simon Chowdhury
- Martin E Gore
